TATA HEALTH (01255) announced that on September 4, 2025, the company received a letter from the Stock Exchange setting out additional guidance for the resumption of trading of shares on the Stock Exchange (the "Additional Resumption Guidance", which together with the preliminary resumption guidance, are collectively referred to as the "Resumption Guidance"): re-compliance with Rule 3.10(2) of the Listing Rules. Additionally, the company's shares continue to be suspended from trading.